VRNA Verona Pharma ADS

Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs

Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs

LONDON and RALEIGH, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the closing of its upsized public offering of 14,260,000 American Depositary Shares (“ADSs”), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share, at a price to the public of $10.50 per ADS, which includes the exercise in full by the underwriters of their option to purchase an additional 1,860,000 ADSs. The aggregate gross proceeds from the offering were approximately $150 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Verona Pharma. All ADSs in the offering were offered by Verona Pharma.

Jefferies, Piper Sandler & Co. and Truist Securities acted as the book-running managers for the offering. BTIG, H.C. Wainwright & Co. and Wedbush PacGrow acted as co-managers for the offering.

The offering was made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) on March 19, 2021 and declared effective on March 29, 2021 (the “Registration Statement”). A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering was filed with the SEC on August 9, 2022. The final prospectus supplement relating to the offering was filed with the SEC on August 11, 2022 and is available on the SEC’s website at Copies of the final prospectus supplement and the accompanying base prospectus relating to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at ; Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at ; or Truist Securities, Inc., Attention: Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta, Georgia 30326 or by e-mail at .

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

No prospectus will be made available in connection with the matters contained in this announcement and no such prospectus is required in accordance with Regulation (EU) 2017/1129 (the “EU Prospectus Regulation”) or the EU Prospectus Regulation as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018, as amended from time to time (the “EUWA”) (the “UK Prospectus Regulation”) to be published.

This announcement is for information purposes only and is directed only at persons whose ordinary activities involve acquiring, holding, managing and disposing of investments (as principal or agent) for the purposes of their business and who have professional experience in matters relating to investments and are: (a) if in a member state of the European Economic Area (the “EEA”) (each a “Relevant State”), qualified investors within the meaning of article 2(e) of the EU Prospectus Regulation ("Qualified Investors"); or (b) if in the United Kingdom, qualified investors within the meaning of article 2(e) of the UK Prospectus Regulation who are also (i) persons who fall within the definition of “investment professional” in article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) persons who fall within article 49(2)(a) to (d) of the Order, or (c) persons to whom it may otherwise be lawfully communicated (all such persons referred to in (i), (ii) and (iii) above together being referred to as “Relevant Persons”).

Any investment or investment activity to which this announcement relates is available only to Qualified Investors in the Relevant States, and to Relevant Persons in the United Kingdom, and will be engaged in only with Qualified Investors in Relevant States and Relevant Persons in the United Kingdom. This announcement must not be acted on or relied on by persons in a Relevant State who are not Qualified Investors, or persons in the United Kingdom who are not Relevant Persons.

For further information please contact:

Verona Pharma plcUS Tel:

UK Tel: +44 (0)203 283 4200
Victoria Stewart, Director of Investor Relations and Communications
  
Argot Partners

(US Investor Enquiries)
Tel:

Kimberly Minarovich / Michael Barron 
  
Optimum Strategic Communications

(International Media and European Investor Enquiries)
Tel: +44 (0)203 882 9621

Mary Clark / Rebecca Noonan / Zoe Bolt 



EN
15/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Verona Pharma ADS

 PRESS RELEASE

Verona Pharma Announces June 2025 Investor Conference Participation

Verona Pharma Announces June 2025 Investor Conference Participation LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:05 a.m. ET / 4:05 p.m. BSTLocation: New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 2:40 p.m. ET / 7:40 p.m. BSTLocation: Miami, FL A webcast of each conferenc...

Verona Pharma: 1 director

A director at Verona Pharma sold/sold after exercising options 14,373 shares at 70.573USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...

 PRESS RELEASE

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies...

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”),...

 PRESS RELEASE

Verona Pharma Reports First Quarter 2025 Financial Results and Provide...

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the...

 PRESS RELEASE

Verona Pharma to Report First Quarter 2025 Financial Results and Provi...

Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch